Department of Electrophysiology, Heart Center Leipzig, University of Leipzig, Struempellstrasse 39, Leipzig, Germany.
Europace. 2019 Jan 1;21(1):91-98. doi: 10.1093/europace/euy132.
Ablation of atrial fibrillation (AF) is recommended in the guidelines as a Class Ia/IIa indication. However, associated complications should not be dismissed; specifically, inguinal vascular complications (IVC). Although IVCs are generally considered trivial, they represent an economic burden for the procedure-performing hospital and the patient. Therefore, the ability to monitor and ultimately minimize potential complications is of considerable interest.
An economic model was developed to calculate the economic impact for certain IVC-types from a large German single-centre perspective in 2015 and 2016. Twenty-nine of 1040 (2.79%) and 48 of 1152 (4.17%) AF-ablation patients had documented IVC in 2015 and 2016 (P = 0.08), respectively. Inguinal vascular complications that required invasive treatment (thrombin, intervention, surgery) occurred in 0.58% of the 2015 and in 0.87% of the 2016 AF-ablation cases. The expected excess costs (incorporating direct costs, benefit lost adjusted for reimbursement) per patient treated with AF-ablation were 139.54€ and 153.31€ in 2015 and 2016, respectively. This was mostly driven by opportunity costs, which could reach 15 544.71€ for certain IVC. Sensitivity analysis revealed the probability of occurrence, length of stay of certain IVC types, and the revenue per day influenced the expected costs per AF-ablation patient.
Even relatively benign complications such as IVC can result in considerable cost increases. Therefore, measures to reduce them should be established and implemented.
指南推荐消融心房颤动(AF)作为 Ia/IIa 类适应证。然而,不应忽视相关并发症,特别是腹股沟血管并发症(IVC)。尽管 IVC 通常被认为是微不足道的,但它们会给进行手术的医院和患者带来经济负担。因此,监测并最终最小化潜在并发症的能力具有重要意义。
从 2015 年和 2016 年德国单一中心的角度,开发了一种经济模型来计算特定 IVC 类型的经济影响。2015 年和 2016 年分别有 29/1040(2.79%)和 48/1152(4.17%)的 AF 消融患者记录有 IVC(P=0.08)。需要侵入性治疗(凝血酶、介入、手术)的腹股沟血管并发症在 2015 年和 2016 年 AF 消融病例中分别占 0.58%和 0.87%。每例接受 AF 消融治疗的患者的预期额外费用(包括直接费用、经报销调整的收益损失)在 2015 年和 2016 年分别为 139.54 欧元和 153.31 欧元。这主要是由机会成本驱动的,对于某些 IVC,机会成本可能高达 15544.71 欧元。敏感性分析显示,IVC 类型的发生概率、住院时间和日收入会影响每例 AF 消融患者的预期费用。
即使是相对良性的并发症,如 IVC,也可能导致相当大的成本增加。因此,应制定并实施降低这些并发症的措施。